MassDevice.com +5 | The top 5 medtech stories for May 18, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters. 5. Teleflex closes $400m debt offering Teleflex said Monday it closed a $400 million debt offering round through the offering of 4.875% senior notes due in 2026. The Wayne, Penn.-based company said it expects to net approximately $393 million from the offering after deducting underwriters discounts and commissions, and intends to use the proceeds to repay borrowings from its revolving credit facility, according to an SEC filing. Read more 4. Edwards touts multi-trial heart valve data Edwards Lifesciences yesterday released results from 3 trials of its surgical heart valves designed for treating aortic valve disease, touting positive clinical results from studies of over 2,000 patients. Data from the trials was presented during late-breaking sessions at the American Association for Thoracic Surgery’s 96th annual meeting this week, the company said. Read more 3. Zimmer Biomet closes Cayenne Medical buy Zimmer Biomet said today that it closed its buyout of Cayenne Medical and its soft tissue reconstruction devices for an unspecified amount. Scottsdale, Ariz.-based ...
The optimal selection of prosthetic heart valve for dialysis-dependent patients remains controversial. We investigated the comparative effectiveness and safety of mechanical prosthesis (MP) and bioprosthesis (BP) for these patients.
Publication date: August 2020Source: IJC Heart &Vasculature, Volume 29Author(s): Yuki Kamo, Shinichiro Fujimoto, Chihiro Aoshima, Yuko O. Kawaguchi, Yui Nozaki, Ayako Kudo, Daigo Takahashi, Kazuhisa Takamura, Makoto Hiki, Nobuo Tomizawa, Kanako K. Kumamaru, Shigeki Aoki, Hiroyuki Daida
Publication date: Available online 30 June 2020Source: American Heart JournalAuthor(s): Helene Eltchaninoff, Nikolaos Bonaros, Bernard Prendergast, Fabian Nietlispach, Mariuca Vasa-Nicotera, Alaide Chieffo, Philippe Pibarot, Peter Bramlage, Lenka Sykorova, Jana Kurucova, Jeroen J. Bax, Stephan Windecker, Nicolas Dumonteil, Didier Tchetche
Schematic illustration of the platform and experimental design with 40 nm polystyrene nanoplastics. Human blastocysts and human induced pluripotent stem cells were exposed for 24 hours to polystyrene nanoitems and used for whole transcriptome sequencing and in depth RNA analysis through Next‐Generation Sequencing technology. In preprocessment, gene IDs were tran slated, scaled, normalized, and used for signaling pathways, analysis, and delivery of the report. AbstractIncreased pollution by plastics has become a serious global environmental problem, but the concerns for human health have been raised after r...
Authors: Ge F, Lu Y, Li Q, Zhang X Abstract Decellularized extracellular matrices (dECMs) from mammalian tissues and organs are particularly interesting as scaffolds for tissue engineering and regeneration when considering their ability to retain chemical compositions and three-dimensional (3D) microstructures that are similar to native ECMs. This review discusses the advantages and disadvantages of different decellularization methods that use various agents, such as ionic and nonionic detergents and biological enzymes. The applications of dECMs as scaffolds or hydrogels for tissue engineering of specific tissues i...
Transcatheter mitral valve implantation (TMVI) is at various levels of preclinical investigation and has proven to be more challenging than transcatheter aortic valve implantation (TAVI) due to more complex anatomy. The purpose of this study is to evaluate the short-term and long-term outcomes of high-risk patients undergoing TMVI for degenerated mitral bioprostheses. In this retrospective, observational study, we reviewed data on the first 26 patients with previous surgical mitral valve replacement or repair with annular ring that underwent TMVI using the balloon-expandable heart-valve system at our institution from 2014 to 2019.
To determine the effect of preoperative opioid use disorder (OUD) on postoperative outcomes in patients undergoing coronary artery bypass grafting (CABG) and heart valve surgery.
Condition: Cerebral Hemorrhage Intervention: Drug: Low molecular weight heparin Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Recruiting
A new polymeric heart valve with a life span potentially longer than current artificial valves that would also prevent the need for the millions of patients with diseased heart valves to require life-long blood thinning tablets has been developed by scientists at the universities of Bristol and Cambridge. The team's latest in-vitro results, published in Biomaterials Science, suggest that the PoliValve could last for up to 25 years.
Publication date: Available online 25 June 2020Source: The LancetAuthor(s): Raj R Makkar, Wen Cheng, Ron Waksman, Lowell F Satler, Tarun Chakravarty, Mark Groh, William Abernethy, Mark J Russo, David Heimansohn, James Hermiller, Stephen Worthley, Bassem Chehab, Mark Cunningham, Ray Matthews, Ravi K Ramana, Gerald Yong, Carlos E Ruiz, Chunguang Chen, Federico M Asch, Mamoo Nakamura